A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis
ARCT-032-02
Phase 2 other active
Quick answer
A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis for Cystic Fibrosis is a Phase 2 program (other) at Arcturus Therapeutics Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Arcturus Therapeutics Holdings
- Indication
- Cystic Fibrosis
- Phase
- Phase 2
- Modality
- other
- Status
- active